메뉴 건너뛰기




Volumn 37, Issue 6, 2010, Pages 1069-1073

Bevacizumab in combination with mFOLFOX6 or FOLFIRI for previously treated metastatic colorectal cancer

Author keywords

Bevacizumab; Chemotherapy of colorectal cencer; Second line therapy

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

EID: 79960819281     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (2)

References (16)
  • 1
    • 34748918351 scopus 로고    scopus 로고
    • Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: A meta-analysis
    • DOI 10.1016/S1470-2045(07)70281-4, PII S1470204507702814
    • Golfinopoulos V, Salanti G, Pavlidis N, et al: Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis. Lancet Oncol 8:898-911, 2007. (Pubitemid 47488054)
    • (2007) Lancet Oncology , vol.8 , Issue.10 , pp. 898-911
    • Golfinopoulos, V.1    Salanti, G.2    Pavlidis, N.3    Ioannidis, J.P.4
  • 2
    • 20544471876 scopus 로고    scopus 로고
    • Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer
    • Kabbinavar FF, Hambleton J, Mass RD, et al: Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23:3706-3712, 2005.
    • (2005) J Clin Oncol , vol.23 , pp. 3706-3712
    • Kabbinavar, F.F.1    Hambleton, J.2    Mass, R.D.3
  • 3
    • 0030856731 scopus 로고    scopus 로고
    • Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders
    • Presta LG, Chen H, O'Connor SJ, et al: Humanization of an anti-vascular anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57:4593-4599, 1997. (Pubitemid 27441066)
    • (1997) Cancer Research , vol.57 , Issue.20 , pp. 4593-4599
    • Presta, L.G.1    Chen, H.2    O'Connor, S.J.3    Chisholm, V.4    Meng, Y.G.5    Krummen, L.6    Winkler, M.7    Ferrara, N.8
  • 4
    • 34248173883 scopus 로고    scopus 로고
    • Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200
    • DOI 10.1200/JCO.2006.09.6305
    • Giantonio BJ, Catalano PJ, Meropol NJ, et al: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the eastern cooperative oncology group study E3200. J Clin Oncol 25:1539-1544, 2007. (Pubitemid 46733080)
    • (2007) Journal of Clinical Oncology , vol.25 , Issue.12 , pp. 1539-1544
    • Giantonio, B.J.1    Catalano, P.J.2    Meropol, N.J.3    O'Dwyer, P.J.4    Mitchell, E.P.5    Alberts, S.R.6    Schwartz, M.A.7    Benson III, A.B.8
  • 5
    • 2542561964 scopus 로고    scopus 로고
    • Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    • Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004.
    • (2004) N Engl J Med , vol.350 , pp. 2335-2342
    • Hurwitz, H.1    Fehrenbacher, L.2    Novotny, W.3
  • 6
    • 20544478429 scopus 로고    scopus 로고
    • Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial
    • Kabbinavar FF, Schulz J, McCleod M, et al: Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 23:3697-3705, 2005.
    • (2005) J Clin Oncol , vol.23 , pp. 3697-3705
    • Kabbinavar, F.F.1    Schulz, J.2    McCleod, M.3
  • 7
    • 49049105525 scopus 로고    scopus 로고
    • Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer results of the TREE study
    • Hochster HS, Hart LL, Ramanathan RK, et al: Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer results of the TREE study. J Clin Oncol 26:3523-3529, 2008.
    • (2008) J Clin Oncol , vol.26 , pp. 3523-3529
    • Hochster, H.S.1    Hart, L.L.2    Ramanathan, R.K.3
  • 8
    • 56749169353 scopus 로고    scopus 로고
    • Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: Results from a large observational cohort study (BRiTE)
    • Grothey A, Sugrue MM, Purdie DM, et al: Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 26:5326-5334, 2008.
    • (2008) J Clin Oncol , vol.26 , pp. 5326-5334
    • Grothey, A.1    Sugrue, M.M.2    Purdie, D.M.3
  • 10
    • 42949149159 scopus 로고    scopus 로고
    • Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study
    • Saltz LB, Clarke S, Diaz-Rubio E, et al: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013-2017, 2008.
    • (2008) J Clin Oncol , vol.26 , pp. 2013-2017
    • Saltz, L.B.1    Clarke, S.2    Diaz-Rubio, E.3
  • 11
    • 84958699263 scopus 로고    scopus 로고
    • Safety and effectiveness of bevacizumab and chemotherapy in elderly patients with metastatic colorectal cancer: Results from the BRiTE observational cohort study. poster #4026
    • Kozloff MF, Sugrue MM, Purdie DM, et al: Safety and effectiveness of bevacizumab and chemotherapy in elderly patients with metastatic colorectal cancer: Results from the BRiTE observational cohort study. ASCO 2008 poster #4026.
    • ASCO 2008
    • Kozloff, M.F.1    Sugrue, M.M.2    Purdie, D.M.3
  • 12
    • 84958701134 scopus 로고    scopus 로고
    • Final efficacy results for bevacizumab plus standard first-line chemotherapies in patients with metastatic colorectal cancer: First BEAT. poster #4025
    • Berry RS, Van Cutsem E, Kretzschmar A, et al: Final efficacy results for bevacizumab plus standard first-line chemotherapies in patients with metastatic colorectal cancer: First BEAT. ASCO 2008 poster #4025.
    • ASCO 2008
    • Berry, R.S.1    Van Cutsem, E.2    Kretzschmar, A.3
  • 16
    • 84958703655 scopus 로고    scopus 로고
    • Japanese source


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.